The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ Stands Firmly Against Full Implementation of Off-Year Price Revision in FY2025
January 9, 2024
- Trade Groups, Academic Societies Urge Govt to Expand Coverage for CGP Testing
December 26, 2023
- Awareness Rate for Drug Lag, Loss at 17.6%, Up 5.2 Points from FY2022: JPMA Poll
December 22, 2023
- Reform Package Is “First Step” towards Global Standard, but More Work Remains: JPMA
December 22, 2023
- EFPIA Japan Names Novo’s Mejlvang as New Vice Chair
December 22, 2023
- Pharma Trade Groups Applaud FY2024 Drug Pricing Reform Outline
December 21, 2023
- JMA, JDA, JPA Call for Mitigation Measures for New LLP Coverage Rule
December 21, 2023
- Generic Use Rate Hits Record 82.2% in July-September: JGA
December 21, 2023
- JEMA Raises Alarm on Drug Loss of Complex Generics, Urge Development Incentives
December 11, 2023
- JA Survey Confirms Narrowing Down of Wholesalers by 4 Drug Makers as of April
December 8, 2023
- Gap between Poll Results and Drug Availability “Inevitable,” FPMAJ Says after JMA’s Criticism
November 22, 2023
- New Group Led by MRI to Issue Clinical Trial Policy Proposals by September 2024
November 22, 2023
- Israel-Palestine Conflict to Have Limited Impact on Japan Pharma Sector for Now: JPMA
November 17, 2023
- JPMA Gearing Up for Drug Pricing Reform Debate towards December: Exec
November 17, 2023
- Policy Veterans’ Group Renews Call for Company-Proposed Pricing, Floats Support System for Biosimilars
November 15, 2023
- PhRMA Chief Presses Japan to Cut LLP Spending, Shift Funds towards Innovation
November 15, 2023
- PhRMA Chair Urges Japan to Maintain On-Patent Drug Prices, Improve Initial Pricing
November 10, 2023
- Diabetes Groups Urge Govt to Build Stable Supply System for GLP-1s, Other Meds
November 8, 2023
- Chuikyo Rep Interview 4 - JMA Rep Says Any Reform Must Ensure Access to Appropriate Healthcare
November 6, 2023
- GHIT Fund, MPP to Bolster Ties to Enhance Drug Access
October 31, 2023
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…